FULC vs. MRVI, DNTH, LENZ, CRMD, SION, ORGO, ABUS, SANA, CDXC, and KALV
Should you be buying Fulcrum Therapeutics stock or one of its competitors? The main competitors of Fulcrum Therapeutics include Maravai LifeSciences (MRVI), Dianthus Therapeutics (DNTH), LENZ Therapeutics (LENZ), CorMedix (CRMD), Sionna Therapeutics (SION), Organogenesis (ORGO), Arbutus Biopharma (ABUS), Sana Biotechnology (SANA), ChromaDex (CDXC), and KalVista Pharmaceuticals (KALV). These companies are all part of the "pharmaceutical products" industry.
Fulcrum Therapeutics vs.
Fulcrum Therapeutics (NASDAQ:FULC) and Maravai LifeSciences (NASDAQ:MRVI) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, media sentiment, valuation, profitability, dividends, community ranking and institutional ownership.
In the previous week, Maravai LifeSciences had 51 more articles in the media than Fulcrum Therapeutics. MarketBeat recorded 54 mentions for Maravai LifeSciences and 3 mentions for Fulcrum Therapeutics. Fulcrum Therapeutics' average media sentiment score of 1.69 beat Maravai LifeSciences' score of 0.09 indicating that Fulcrum Therapeutics is being referred to more favorably in the media.
Fulcrum Therapeutics received 35 more outperform votes than Maravai LifeSciences when rated by MarketBeat users. Likewise, 60.87% of users gave Fulcrum Therapeutics an outperform vote while only 60.58% of users gave Maravai LifeSciences an outperform vote.
Fulcrum Therapeutics has a beta of 2.2, indicating that its stock price is 120% more volatile than the S&P 500. Comparatively, Maravai LifeSciences has a beta of -0.08, indicating that its stock price is 108% less volatile than the S&P 500.
Fulcrum Therapeutics has higher earnings, but lower revenue than Maravai LifeSciences. Fulcrum Therapeutics is trading at a lower price-to-earnings ratio than Maravai LifeSciences, indicating that it is currently the more affordable of the two stocks.
Fulcrum Therapeutics presently has a consensus price target of $8.63, indicating a potential upside of 177.33%. Maravai LifeSciences has a consensus price target of $7.59, indicating a potential upside of 230.16%. Given Maravai LifeSciences' stronger consensus rating and higher probable upside, analysts plainly believe Maravai LifeSciences is more favorable than Fulcrum Therapeutics.
Fulcrum Therapeutics has a net margin of 0.00% compared to Maravai LifeSciences' net margin of -81.13%. Maravai LifeSciences' return on equity of -6.61% beat Fulcrum Therapeutics' return on equity.
89.8% of Fulcrum Therapeutics shares are held by institutional investors. Comparatively, 50.3% of Maravai LifeSciences shares are held by institutional investors. 4.1% of Fulcrum Therapeutics shares are held by insiders. Comparatively, 0.6% of Maravai LifeSciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Summary
Fulcrum Therapeutics and Maravai LifeSciences tied by winning 9 of the 18 factors compared between the two stocks.
Get Fulcrum Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for FULC and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Fulcrum Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:FULC) was last updated on 3/26/2025 by MarketBeat.com Staff
